CL2018000914A1 - Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular - Google Patents

Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular

Info

Publication number
CL2018000914A1
CL2018000914A1 CL2018000914A CL2018000914A CL2018000914A1 CL 2018000914 A1 CL2018000914 A1 CL 2018000914A1 CL 2018000914 A CL2018000914 A CL 2018000914A CL 2018000914 A CL2018000914 A CL 2018000914A CL 2018000914 A1 CL2018000914 A1 CL 2018000914A1
Authority
CL
Chile
Prior art keywords
gaba
psicologicos
neurologicos
inactivadores
hepatocelular
Prior art date
Application number
CL2018000914A
Other languages
English (en)
Spanish (es)
Inventor
Richard B Silverman
Kenji Takaya
Hoang V Le
Jose I Juncosa
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of CL2018000914A1 publication Critical patent/CL2018000914A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2018000914A 2015-10-09 2018-04-09 Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular CL2018000914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562239330P 2015-10-09 2015-10-09

Publications (1)

Publication Number Publication Date
CL2018000914A1 true CL2018000914A1 (es) 2018-08-31

Family

ID=58488679

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000914A CL2018000914A1 (es) 2015-10-09 2018-04-09 Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular

Country Status (20)

Country Link
US (3) US9670141B2 (enExample)
EP (1) EP3341355B1 (enExample)
JP (1) JP6841821B2 (enExample)
KR (1) KR102745965B1 (enExample)
CN (1) CN108137484B (enExample)
AU (1) AU2016334396B2 (enExample)
BR (1) BR112018007026B1 (enExample)
CA (1) CA3001330A1 (enExample)
CL (1) CL2018000914A1 (enExample)
CO (1) CO2018003828A2 (enExample)
DK (1) DK3341355T3 (enExample)
ES (1) ES2825349T3 (enExample)
HU (1) HUE053429T2 (enExample)
IL (1) IL258516A (enExample)
LT (1) LT3341355T (enExample)
MX (1) MX380592B (enExample)
PE (1) PE20190349A1 (enExample)
PL (1) PL3341355T3 (enExample)
PT (1) PT3341355T (enExample)
WO (1) WO2017062942A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373033B (es) 2014-08-21 2020-05-27 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
JP6841821B2 (ja) * 2015-10-09 2021-03-10 ノースウェスタン ユニバーシティ てんかん、嗜癖および肝細胞癌の処置のためのgabaアミノトランスフェラーゼ不活性化剤としての(s)−3−アミノ−4−(ジフルオロメチレニル)シクロペント−1−エン−1−カルボン酸および関連化合物
EP3359542B1 (en) 2015-10-09 2021-03-17 Boehringer Ingelheim International GmbH Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CA3051699A1 (en) * 2017-02-08 2018-08-16 Ovid Therapeutics Inc. Methods of treating seizure disorders and prader-willi syndrome
CN112261938A (zh) * 2018-02-08 2021-01-22 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途
US11771671B2 (en) * 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
JP2021519753A (ja) * 2018-03-29 2021-08-12 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. 眼障害の治療における(1s,3s)−3−アミノ−4−(ジフルオロメチリデン)シクロペンタン−1−カルボン酸および(s)−3−アミノ−4−(ジフルオロメチルエニル)シクロペンタ−1−エン−1−カルボン酸の使用
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
IL278932B2 (en) * 2018-05-25 2024-03-01 Univ Northwestern PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-l-ENE-l-CARBOXYLIC ACID
WO2019236938A1 (en) * 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US11203596B2 (en) 2019-02-25 2021-12-21 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
CN110935495B (zh) * 2019-11-29 2021-02-23 中国科学院电子学研究所 Gaba和电生理微纳同步传感检测芯片及其制备方法
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
WO2022187523A1 (en) * 2021-03-03 2022-09-09 Northwestern University (s)-3-amino-4,4-dihalocyclopent-1-enecarboxylic acid as selective inactivators of human ornithine aminotransferase
US20250171397A1 (en) * 2022-02-27 2025-05-29 Northwestern University (3s,4r)-3-amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic acid and related compounds as selective inactivators of ornithine aminotransferase
AU2023302929A1 (en) * 2022-07-06 2025-01-23 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of cancer
CN120659624A (zh) * 2023-02-17 2025-09-16 奥维德医疗公司 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗多发性硬化中的用途
JP2026506099A (ja) * 2023-02-17 2026-02-20 オービッド・セラピューティクス・インコーポレイテッド 糖尿病および前糖尿病の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペント-1-エン-1-カルボン酸の使用
CN120641130A (zh) * 2023-02-17 2025-09-12 奥维德医疗公司 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗类风湿性关节炎中的用途
WO2024173750A2 (en) * 2023-02-17 2024-08-22 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
IL177609A (en) * 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
AR087700A1 (es) * 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
JP6841821B2 (ja) * 2015-10-09 2021-03-10 ノースウェスタン ユニバーシティ てんかん、嗜癖および肝細胞癌の処置のためのgabaアミノトランスフェラーゼ不活性化剤としての(s)−3−アミノ−4−(ジフルオロメチレニル)シクロペント−1−エン−1−カルボン酸および関連化合物

Also Published As

Publication number Publication date
BR112018007026B1 (pt) 2022-06-21
PL3341355T3 (pl) 2021-03-08
US9670141B2 (en) 2017-06-06
KR102745965B1 (ko) 2024-12-20
EP3341355B1 (en) 2020-09-30
PT3341355T (pt) 2020-10-21
WO2017062942A3 (en) 2018-03-01
BR112018007026A2 (pt) 2018-10-16
US20170239202A1 (en) 2017-08-24
HK1253002A1 (zh) 2019-06-06
CA3001330A1 (en) 2017-04-13
KR20180052782A (ko) 2018-05-18
US20170101364A1 (en) 2017-04-13
CN108137484B (zh) 2021-02-12
PE20190349A1 (es) 2019-03-07
EP3341355A2 (en) 2018-07-04
JP6841821B2 (ja) 2021-03-10
AU2016334396A1 (en) 2018-04-19
US9993449B2 (en) 2018-06-12
US20180271816A1 (en) 2018-09-27
MX380592B (es) 2025-03-12
WO2017062942A2 (en) 2017-04-13
LT3341355T (lt) 2020-11-10
CO2018003828A2 (es) 2018-07-19
JP2018531941A (ja) 2018-11-01
DK3341355T3 (da) 2020-10-26
CN108137484A (zh) 2018-06-08
HUE053429T2 (hu) 2021-07-28
EP3341355A4 (en) 2019-04-10
ES2825349T3 (es) 2021-05-17
IL258516A (en) 2018-05-31
AU2016334396B2 (en) 2021-04-08
MX2018004302A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
NI201600056A (es) Inhibidores de bromodominio
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
HUE059559T2 (hu) 5HT agonisták az epilepsziás rendellenességek kezelésére
BR112017006664A2 (pt) terapias de combinação
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
MX375438B (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
UY34719A (es) Proceso para la producción de inhibidores de crr
BR112017009289A2 (pt) métodos de administrar composições de amantadina
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
EP3626256C0 (fr) Composition pour le traitement des lésions tissulaires
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
LT3322438T (lt) Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.